Company intelligence / Profile preview

Samuel Fortin

Ownership: Private
Development stage: Other

Overview

SCF Pharma develops and commercializes innovative omega‑3 and lipid-based health ingredients. Their MAG-O3 monoglyceride omega‑3 technology has been clinically studied, including a topical formulation in clinical trials for dry eye disease. The company also conducts its own human clinical studies to validate efficacy.

Therapeutic areas: Metabolic DisordersOphthalmologyOther
Modalities: Small moleculeLipid-based therapyDietary supplement
Industry: Biotech

Partnerships

Not specified; possible collaborations with branded supplement companies via ingredient supply partnerships

Beyond the preview

Go deeper on Samuel Fortin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Samuel Fortin.

Explore the full profile